1268 related articles for article (PubMed ID: 16368444)
1. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
2. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
Obering CD; Chen JJ; Swope DM
Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
6. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.
Kolls BJ; Stacy M
Clin Neuropharmacol; 2006; 29(5):292-301. PubMed ID: 16960475
[TBL] [Abstract][Full Text] [Related]
9. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
10. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine in dopaminergic therapy.
Subramony JA
Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine (Apokyn) for advanced Parkinson's Disease.
Med Lett Drugs Ther; 2005 Jan; 47(1200):7-8. PubMed ID: 15647705
[TBL] [Abstract][Full Text] [Related]
13. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
[TBL] [Abstract][Full Text] [Related]
14. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
16. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
17. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
18. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
Pfeiffer RF; Gutmann L; Hull KL; Bottini PB; Sherry JH;
Parkinsonism Relat Disord; 2007 Mar; 13(2):93-100. PubMed ID: 17055329
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
20. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
